Bosh sahifaGLAXO • NSE
add
GlaxoSmithKline Pharmaceuticals Ltd
Yopilish kursi
3 388,10 ₹
Kunlik diapazon
3 345,10 ₹ - 3 450,00 ₹
Yillik diapazon
1 921,00 ₹ - 3 515,70 ₹
Bozor kapitalizatsiyasi
569,81 mlrd INR
Oʻrtacha hajm
230,22 ming
Narx/foyda
61,33
Dividend daromadliligi
1,25%
Asosiy maydon
NSE
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (INR) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 9,74 mlrd | 4,79% |
Joriy xarajat | 2,77 mlrd | -8,47% |
Sof foyda | 2,63 mlrd | 35,17% |
Sof foyda marjasi | 26,98 | 28,97% |
Har bir ulushga tushum | 54,52 | — |
EBITDA | 3,32 mlrd | 32,98% |
Amaldagi soliq stavkasi | 26,69% | — |
Balans
Jami aktivlari
Jami passivlari
| (INR) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 24,98 mlrd | 34,54% |
Jami aktivlari | 41,08 mlrd | 15,50% |
Jami passivlari | 21,57 mlrd | 21,24% |
Umumiy kapital | 19,51 mlrd | — |
Tarqatilgan aksiyalar | 169,41 mln | — |
Narxi/balansdagi bahosi | 29,41 | — |
Aktivlardan daromad | — | — |
Kapitaldan daromad | 44,16% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (INR) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 2,63 mlrd | 35,17% |
Operatsiyalardan naqd pul | — | — |
Sarmoyadan naqd pul | — | — |
Moliyadan naqd pul | — | — |
Naqd pulning sof oʻzgarishi | — | — |
Boʻsh pul | — | — |
Haqida
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases. It also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, and others. Wikipedia
Tashkil etilgan
13-noy, 1924
Xodimlar soni
3 113
